Evolus Inc (EOLS)

NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA

Evolus Inc is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.

Evolus Inc is a global performance beauty company selling injectable aesthetic products to licensed practitioners in the cash-pay market. The company offers Jeuveau, a botulinum toxin formulation for temporary improvement of frown lines, and Evolysse, a portfolio of injectable hyaluronic acid gels for wrinkles and facial volume.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Evolus Inc stock.

Our verdict on EOLS

Overvalued: intrinsic value $4.85 per share, market price $6.69, margin of safety -38.0% (as of 2026-11-17).

A 1.3x revenue multiple, discounted for its losses, values the shares at $4.85; the price of $6.69 is 38% above that value.

ETFs with the most weight in EOLS

17 more funds hold it; the full list is part of the paid plan.

More on EOLS

Browse

Peers in Drug Manufacturers - Specialty & Generic

All 82 Drug Manufacturers - Specialty & Generic stocks

Cheaper than EOLS in Drug Manufacturers - Specialty & Generic

16 more in this industry show a wider margin of safety.

Is EOLS undervalued or overvalued?

EOLS is overvalued (as of the 2026-11-17 close). A 1.3x revenue multiple, discounted for its losses, values the shares at $4.85; the price of $6.69 is 38% above that value.

What is the intrinsic value of EOLS?

$4.85 per share (as of the 2026-11-17 close), against a market price of $6.69. That is a margin of safety of -38.0%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.